Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398623 | 0.89 | FABP5 (0.51) | FABP5KCNN4FABP7KMT2AMDM4 | |
| SCHEMBL9224988 | 0.82 | FABP5 (0.43) | FABP5GAAFABP7MDM2KMT2A | |
| SCHEMBL1311053 | 0.79 | FABP5 (0.44) | FABP5GAAFABP7MDM2KMT2A | |
| SCHEMBL12061892 | 0.77 | MDM2 (0.49) | FABP5GAAMDM2KMT2AKIF11 | |
| SCHEMBL14946789 | 0.77 | FABP5 (0.41) | FABP5GAAFABP7MDM2KMT2A | |
| SCHEMBL7801461 | 0.77 | KMT2A (0.52) | FABP5GAAMDM2KMT2AMDM4 | |
| SCHEMBL28069714 | 0.77 | FABP5 (0.45) | FABP5FABP7MDM2KMT2AKIF11 | |
| SCHEMBL27597924 | 0.76 | CHRM2 (0.52) | FABP5FABP7KMT2AMDM4TP53 | |
| SCHEMBL30990574 | 0.76 | NPC1 (0.52) | FABP5KCNN4FABP7KIF11ALDH1A1 | |
| SCHEMBL27597932 | 0.75 | FABP5 (0.46) | FABP5FABP7KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | disclosed |
| CN-118725014-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118702766-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118702767-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3862431-B1 | METHOD FOR PRODUCING HAIRPIN SINGLE-STRAND RNA MOLECULES | TORAY INDUSTRIES (JP) | 2024-06-26 | — | — | EP | disclosed |
| CN-111954539-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240110186-A1 | METHOD OF PRODUCING HAIRPIN SINGLE-STRANDED RNA MOLECULES | TORAY INDUSTRIES, INC. (JP) | 2024-04-04 | — | — | US | disclosed |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| US-11891602-B2 | Method of producing hairpin single-stranded RNA molecules | TORAY INDUSTRIES, INC. (JP) | 2024-02-06 | — | — | US | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4218785-A2 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3723783-B1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4092038-A1 | OPIOID AGONIST PEPTIDES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | FABP5 4568/4885GAA 1903/4885KCNN4 3649/4885 |
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | FABP5 440/4885GAA 1795/4885KCNN4 3760/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | FABP5 4568/4885GAA 1903/4885KCNN4 3649/4885 |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | FABP5 440/4885GAA 1795/4885KCNN4 3760/4885 |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | FABP5 440/4885GAA 1795/4885KCNN4 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.